UK launches oral Wegovy weight‑loss pill, pricing similar to injection

The UK's first licensed oral formulation of the Wegovy weight‑loss drug, containing the GLP‑1 agonist semaglutide, became available on July 6, 2026. The tablet offers a needle‑free alternative to the weekly injection and can be stored at room temperature, appealing to the estimated 2.4 million Britons who fear needles.

Pharmacy pricing varies by dose. Starting doses are estimated at £98.50‑£185 per month, while maintenance doses range from £170‑£200, broadly comparable to the injection, which costs £89‑£250 per month depending on the dose. Boots began selling the pill from £79, and pharmacies reported strong demand, with around 70,000 British consumers signing up.

Clinicians note that the pill must be taken each morning on an empty stomach with a small amount of water, and a delay before eating is required; missed doses may affect efficacy. While convenient for many, some users find the daily routine less suitable than the weekly injection. Health officials also warned of a likely rise in counterfeit versions as the product gains popularity.